LATE-BREAKING ABSTRACT: Randomised, double blind, placebo-controlled phase III study of inhaled dry powder mannitol in cystic fibrosis (CF)
D. B. Bilton, P. R. Robinson, P. C. Cooper, B. C. Charlton (London, United Kingdom; Melbourne, Sydney, Australia)
Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. B. Bilton, P. R. Robinson, P. C. Cooper, B. C. Charlton (London, United Kingdom; Melbourne, Sydney, Australia). LATE-BREAKING ABSTRACT: Randomised, double blind, placebo-controlled phase III study of inhaled dry powder mannitol in cystic fibrosis (CF). Eur Respir J 2009; 34: Suppl. 53, 1619
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study Source: ERJ Open Res, 6 (4) 00132-2020; 10.1183/23120541.00132-2020 Year: 2020
RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis Source: Eur Respir J, 51 (1) 1702053; 10.1183/13993003.02053-2017 Year: 2018
RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis Source: Eur Respir J, 51 (1) 1702052; 10.1183/13993003.02052-2017 Year: 2018
A randomised, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis Year: 2008
LATE-BREAKING ABSTRACT: Inhaled mannitol for non-cystic fibrosis bronchiectasis: results of a 12 month, multi-centre, double-blind, controlled study. Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013
RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations Source: Virtual Congress 2021 – ALERT: COPD Year: 2021
LATE-BREAKING ABSTRACT: The benefits of [italic]Nigella sativa[/italic] oil supplementation on asthma inflammation: A randomised, double-blind, placebo-controlled, phase II trial Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016
Nasal high-flow therapy (NHFT) during exercise in patients with cystic fibrosis (CF): a randomized crossover trial Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020
RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021
Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study Source: Eur Respir J, 59 (2) 2100746; 10.1183/13993003.00746-2021 Year: 2022
Randomized, double-blind, controlled trial of preventive inhalation of hypertonic saline in infants with CF (PRESIS) Source: International Congress 2018 – Cystic fibrosis: microbiological aspects and new treatments Year: 2018
A double-blind double dummy randomised placebo-controlled cross-over design clinical trial of formoterol delivered by two different dry powder devices in prevention of bronchoconstriction induced by methacholine in mild to moderate persistent asthma in adult patients Source: Annual Congress 2009 - Airway hyperresponsiveness: mechanism and assessment Year: 2009
Paracetamol increases airway resistance in stable asthmatics: A double blind, randomized, placebo controlled study Source: Annual Congress 2010 - New or old physiological parameters in chronic airway disorders? Year: 2010
Inhaled dry powder mannitol in cystic fibrosis (CF): Microbiology results from the 6 month double-blind CF301 study Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010
Short-term effect of a single dose of inhaled procaterol on exercise performance in COPD: a randomized, double blind, placebo-controlled, crossover trial Source: Annual Congress 2008 - Physiological response to exercise performance Year: 2008
A single centre, double blind, double dummy, placebo controlled, randomized, three period cross-over phase III trial to demonstrate therapeutic equivalence between a generic and branded inhalation product of ipratropium bromide in subjects with Source: Eur Respir J 2001; 18: Suppl. 33, 71s Year: 2001
Effect of borago extract on moderate persistent asthma, a phase two randomized, double blind placebo-controlled clinical trial Source: International Congress 2016 – Asthma management Year: 2016
Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
The effect of high dose N-acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients — A double blinded randomized placebo controlled trial Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013